

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>ABBOTT LABORATORIES</u> (Last) (First) (Middle) <u>100 ABBOTT PARK ROAD</u> (Street) <u>ABBOTT PARK IL 60064-6092</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Mylan N.V. [MYL]</u> 3. Date of Earliest Transaction (Month/Day/Year) <u>03/31/2015</u> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below) X Form filed by One Reporting Person Form filed by More than One Reporting Person
--	---	---

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares, nominal value euro 0.01 per share	03/31/2015		J		35,000,000	D	\$56.8912	75,000,000	I	By Subsidiaries

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Call Option (Obligation to Sell)	\$56.8912	03/31/2015		J		1	03/31/2015	04/30/2015	Ordinary Shares	5,250,000	\$0	1	I	By Subsidiaries

1. Name and Address of Reporting Person* <u>ABBOTT LABORATORIES</u> (Last) (First) (Middle) <u>100 ABBOTT PARK ROAD</u> (Street) <u>ABBOTT PARK IL 60064-6092</u> (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>Laboratoires Fournier S.A.S.</u> (Last) (First) (Middle) <u>100 ABBOTT PARK ROAD</u> (Street) <u>ABBOTT PARK IL 60064-6092</u> (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>Abbott Established Products Holdings Gibraltar Ltd</u> (Last) (First) (Middle) <u>100 ABBOTT PARK ROAD</u> (Street)

(Street)		
ABBOTT PARK	IL	60064-6092
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*

[Abbott Investments Luxembourg S.A R.L.](#)

(Last)	(First)	(Middle)
100 ABBOTT PARK ROAD		
(Street)		
ABBOTT PARK	IL	60064-6092
(City)	(State)	(Zip)

Explanation of Responses:

Remarks:

The Ordinary Shares of Mylan N.V. ("Mylan") described in this report are held directly by Laboratoires Fournier S.A.S., Abbott Established Products Holdings (Gibraltar) Limited and Abbott Investments Luxembourg S.a r.l (collectively, the "Subsidiaries"). Each of the Subsidiaries is an indirect, wholly-owned subsidiary of Abbott Laboratories ("Abbott"). In Abbott's capacity as the ultimate corporate parent of the Subsidiaries, Abbott may be deemed to indirectly beneficially own such Ordinary Shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Securities and Exchange Commission thereunder. On March 31, 2015, the Subsidiaries entered into an Underwriting Agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC and Goldman Sachs & Co., as representatives of the several underwriters named therein, and Mylan relating to an underwritten public resale offering by the Subsidiaries of an aggregate of 35,000,000 Ordinary Shares. The purchase price to be received by the Subsidiaries pursuant to the Underwriting Agreement is \$56.89125 per Ordinary Share. Pursuant to the Underwriting Agreement, Abbott Investments Luxembourg S.a r.l, for no additional consideration, granted the underwriters a 30-day option to purchase up to an additional 5,250,000 Ordinary Shares at the same price per Ordinary Share.

[ABBOTT LABORATORIES](#)
[Thomas C. Freyman](#)

[03/31/2015](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.